organization · Reporting owner
Longitude Venture Partners L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COLLEGIUM PHARMACEUTICAL, INC
Report date December 08, 2017 · Filed December 12, 2017
Jointly reported with Longitude Capital Partners, LLC, Tammenoms Bakker Juliet, ENRIGHT PATRICK G, Longitude Capital Associates, L.P.
Section 16 reporting ended · disclosed 2017-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LVP | 2,276,222 |
Reported balance
After 2017-12-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-12-08 · Sale · Disposed 980,350 · Balance 2,276,222 F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy LCA | 45,620 |
Reported balance
After 2017-12-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-12-08 · Sale · Disposed 19,650 · Balance 45,620 F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.
CORCEPT THERAPEUTICS INC
Report date November 28, 2016 · Filed December 01, 2016
Jointly reported with Longitude Capital Partners, LLC, Tammenoms Bakker Juliet, Longitude Capital Associates, L.P.
Section 16 reporting ended · disclosed 2016-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,834,849 |
Reported balance
After 2016-11-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2016-11-28 · Other · Disposed 2,941,050 · Balance 10,834,849 F1: Represents a pro rata distribution from Longitude Venture Partners, L.P. ("LVP") to its partners for no consideration. Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, received a pro rata allocation of the distributed shares in accordance with its ownership. F2: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. This report is filed jointly by LVP, Longitude Capital, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy LCA | 121,153 |
Reported balance
After 2016-11-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2016-11-28 · Other · Disposed 58,950 · Balance 121,153 F3: Represents a pro rata distribution from LCA to its partners for no consideration. LCP, which is the sole general partner of LCA, received a pro rata allocation of the distributed shares in accordance with its ownership. F4: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LCA. This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution from Longitude Venture Partners, L.P. ("LVP") to its partners for no consideration. Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, received a pro rata allocation of the distributed shares in accordance with its ownership.
F2: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. This report is filed jointly by LVP, Longitude Capital, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein.
F3: Represents a pro rata distribution from LCA to its partners for no consideration. LCP, which is the sole general partner of LCA, received a pro rata allocation of the distributed shares in accordance with its ownership.
F4: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LCA. This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2017 Filed Dec 12, 2017 16:20 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 19,650 | $17.34 | $340,731.00 |
DisclosureSEC source: 0001209191-17-065191 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 45,620 F1 · ownership.nature: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 16:20 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 980,350 | $17.34 | $16,999,269.00 |
DisclosureSEC source: 0001209191-17-065191 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 2,276,222 F1 · ownership.nature: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 28, 2016 Filed Dec 1, 2016 02:52 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 58,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152569 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 121,153 F3 · kind: Represents a pro rata distribution from LCA to its partners for no consideration. LCP, which is the sole general partner of LCA, received a pro rata allocation of the distributed shares in accordance with its ownership. F4 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LCA. This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 28, 2016 Filed Dec 1, 2016 02:52 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 2,941,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152569 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,834,849 F1 · kind: Represents a pro rata distribution from Longitude Venture Partners, L.P. ("LVP") to its partners for no consideration. Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, received a pro rata allocation of the distributed shares in accordance with its ownership. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. This report is filed jointly by LVP, Longitude Capital, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 25, 2016 Filed Nov 26, 2016 02:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 290 | $9.39 | $2,722.20 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 6 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,103 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.4600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 25, 2016 Filed Nov 26, 2016 02:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 14,451 | $9.39 | $135,650.09 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 5 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,775,899 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.4600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 23, 2016 Filed Nov 26, 2016 02:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 248 | $9.30 | $2,307.34 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 4 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,393 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.3400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 23, 2016 Filed Nov 26, 2016 02:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 12,352 | $9.30 | $114,920.54 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 3 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,790,350 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.3400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 22, 2016 Filed Nov 26, 2016 02:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 189 | $9.33 | $1,763.31 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,641 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.300 to $9.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 22, 2016 Filed Nov 26, 2016 02:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 9,411 | $9.33 | $87,801.81 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,802,702 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.300 to $9.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 02:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,327 | $9.39 | $21,841.22 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 6 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,830 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3300 to $9.4800. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 02:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 116,058 | $9.39 | $1,089,320.39 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 5 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,812,113 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3300 to $9.4800. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 02:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,976 | $9.47 | $18,719.83 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 4 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 183,157 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.4500 to $9.5400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 02:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 98,586 | $9.47 | $933,964.33 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 3 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,928,171 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.4500 to $9.5400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 17, 2016 Filed Nov 22, 2016 02:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,389 | $9.64 | $61,611.68 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 185,133 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5300 to $9.8000. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 17, 2016 Filed Nov 22, 2016 02:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 318,764 | $9.64 | $3,073,968.76 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,026,757 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5300 to $9.8000. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 342 | $9.51 | $3,251.98 |
DisclosureSEC source: 0001209191-16-151019 · doc4.xml · nonDerivative · entry 4 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 191,522 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.5450. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 17,052 | $9.51 | $162,142.35 |
DisclosureSEC source: 0001209191-16-151019 · doc4.xml · nonDerivative · entry 3 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,345,521 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.5450. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 15, 2016 Filed Nov 18, 2016 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,094 | $9.55 | $29,558.22 |
DisclosureSEC source: 0001209191-16-151019 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 191,864 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.7200. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 15, 2016 Filed Nov 18, 2016 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 154,359 | $9.55 | $1,474,653.27 |
DisclosureSEC source: 0001209191-16-151019 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,362,573 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.7200. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.